7Baggers
 EVerZom enters research and licensing agreement with GENFIT  Pharmafile Fri, 14 Nov 2025 11:57:06 GMT
 Genfit and Everzom form research collaboration in liver failure  BioWorld MedTech Mon, 10 Nov 2025 15:18:31 GMT
 GENFIT Unveils Promising Preclinical Data for ACLF Treatment  TipRanks Mon, 10 Nov 2025 13:30:46 GMT
 everzom and genfit team up on exosome therapy for severe liver disease  The Pharma Letter Mon, 10 Nov 2025 11:37:06 GMT
 GENFIT Presents Promising New Preclinical Data on  GlobeNewswire Mon, 10 Nov 2025 06:30:00 GMT
 genfit to delist american depositary shares from nasdaq  MSN Mon, 03 Nov 2025 22:38:59 GMT
 genfit to delist american depositary shares from nasdaq  MSN Sun, 02 Nov 2025 22:45:14 GMT

Genfit SA
(NASDAQ:GNFT) 

GNFT stock logo

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for ...

Founded: 1999
Full Time Employees: 203
CEO: Pascal Prigent  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends